Medical Chronicle May 2017 | Page 3

W H E N E FF E MILD TO MO CTIVE RELIEF INFLAM MAT DERATE PAIN O OF WITHOUT F ORY ORIGIN WI F EVER IS N TH 1, OR EEDED 2 Myprodo l’s COMBIN original formulati ES THE on DIFF ACTIONS of codein ERENT e, ibupro and para fen cetamol in an OP RATIO O T IMISED F 1:20:2 5 for effe of pain, ctive reli infl amma ef tion and Myprodo fever. 1,2 l suspen sio a pleasa nt blackc n is available in urrant fl a vour. 2 ? T N E M O M L O D O R P MY ® My patient. My reputation. Myprodol ® . References: 1. Mitchell D, Gelgor L, Weber J. Antihypernociceptive synergy between ibuprofen, paracetamol and codeine in rats. European Journal of Pharmacology 2010;642:86-92. 2. Myprodol ® Suspension approved package insert, June 1994. MYPRODOL ® Suspension. Each 10 ml contains codeine phosphate 10 mg; ibuprofen 200 mg; paracetamol 250 mg. Reg. No. Y/2.8/119. For full prescribing information refer to the package insert approved by the medicines regulatory authority. 1023659 02/2017. Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryan- ston, 2021, South Africa. Tel. +27 11 635 0000. www.adcock.com